Market Overview

Data from BioTime's OpRegen® Program to Be Presented at AAO 2018

Share:
  • Presentation to include data from new as well as previously treated
    patients

BioTime, Inc. (NYSE:BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that its
abstract "PI/IIa Study of Subretinally Transplanted Human Embryonic Stem
Cell-Derived RPE Cells in Advanced Dry-Form AMD Patients," has been
accepted for an oral presentation at the upcoming American Academy of
Ophthalmology (AAO) meeting taking place from October 27th
– October 30th, 2018, in Chicago, Illinois.

"We are delighted that the AAO has accepted our abstract for an oral
presentation at the upcoming meeting," said Adi Mohanty, Co-Chief
Executive Officer of BioTime. "We look forward to sharing more data from
the ongoing OpRegen clinical trial where we have observed signals that
may suggest structural improvement in the retina."

The AAO is the world's largest association of eye physicians and
surgeons. It is comprised of more than 30,000 medical doctors, whose
mission is to protect sight and empower lives by serving as an advocate
for patients and the public, leading ophthalmic education, and advancing
the profession of ophthalmology.

About OpRegen®

OpRegen®, which is being studied for the treatment of the dry
form of AMD, consists of a suspension of retinal pigment epithelial
(RPE) cells that are delivered subretinally during a simple intraocular
injection. RPE cells are essential components of the back lining of the
retina, and function to help nourish the retina including
photoreceptors. A proprietary process that drives the differentiation of
human pluripotent stem cells is used to generate high purity OpRegen® RPE
cells. OpRegen® RPE cells are also "xeno-free," meaning that
no animal products are used at any point in the derivation and
production process. The avoidance of the use of animal products
eliminates some potential safety concerns. Preclinical studies in rats
have shown that following a single subretinal injection of OpRegen®,
the cells can rapidly organize into its natural monolayer structure in
the subretinal space and survive throughout the lifetime of the animal.
OpRegen® is designed to be an "off-the-shelf" allogeneic
(non-patient specific) product. Unlike treatments that require multiple,
frequent injections into the eye, it is expected that OpRegen® will
be administered in a single procedure. OpRegen® was granted
Fast Track designation from the FDA, which allows more frequent
interactions with the agency, and eligibility for accelerated approval
and priority review. OpRegen® is a registered trademark
of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of BioTime,
Inc.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two platform
technologies: cell replacement and cell/drug delivery. With its cell
replacement platform, BioTime is producing new cells and tissues with
its proprietary pluripotent cell technologies. These cells and tissues
are developed to replace those that are either rendered dysfunctional or
lost due to degenerative diseases or injuries. BioTime's cell/drug
delivery programs are based upon its proprietary HyStem® cell
and drug delivery matrix technology. HyStem® was
designed, in part, to provide for the transfer, retention and/or
engraftment of cellular replacement therapies. BioTime's lead cell
delivery clinical program is Renevia®, which consists of
HyStem® combined with the patient's own adipose (fat)
progenitor cells. Renevia® met its primary endpoint in an EU
pivotal clinical trial for the treatment of facial lipoatrophy in HIV
patients in 2017. BioTime has submitted Renevia® for
CE Mark approval in the EU. There were no device related serious adverse
events reported to date. BioTime's lead cell replacement product
candidate is OpRegen®, a retinal pigment epithelium
transplant therapy, which is in a Phase I/IIa multicenter clinical trial
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. There have been no unexpected
serious adverse events reported to date. BioTime also has significant
equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE:AST)
and OncoCyte Corporation (NYSE:OCX), and a private
company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on TwitterLinkedInFacebookYouTube,
and Google+.

To receive ongoing BioTime corporate communications, please click on the
following link to join the Company's email alert list: http://news.biotime.com.

View Comments and Join the Discussion!